News
IMMX
8.07
-6.81%
-0.59
Immix Biopharma reports Q3 results
Seeking Alpha · 11h ago
Immix Biopharma Q3 EPS $(0.19), Inline
Benzinga · 11h ago
Press Release: Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
Dow Jones · 12h ago
Press Release: Immix Biopharma Reports Third -2-
Dow Jones · 12h ago
IMMX's Cash Runway Now Extends Exactly as Far as Its Promises Do
Barchart · 17h ago
Weekly Report: what happened at IMMX last week (1102-1106)?
Weekly Report · 3d ago
Immix Biopharma To Present An NXC-201 Abstract At American Society Of Hematology Annual Meeting, December 12-15
Benzinga · 11/04 14:18
Weekly Report: what happened at IMMX last week (1026-1030)?
Weekly Report · 11/02 10:23
Weekly Report: what happened at IMMX last week (1019-1023)?
Weekly Report · 10/26 10:22
Immix Biopharma price target raised to $20 from $19 at Morgan Stanley
TipRanks · 10/20 12:05
Weekly Report: what happened at IMMX last week (1012-1016)?
Weekly Report · 10/19 10:22
Weekly Report: what happened at IMMX last week (1005-1009)?
Weekly Report · 10/12 10:28
Weekly Report: what happened at IMMX last week (0928-1002)?
Weekly Report · 10/05 10:28
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Barchart · 10/05 07:45
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
NASDAQ · 10/02 16:13
Immix Biopharma Consensus Price Target Increased by 10.16% to $25.04
NASDAQ · 10/02 11:46
Immix Biopharma Prices $125 Million Equity Offering
TipRanks · 09/30 21:29
Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC), Immix Biopharma (IMMX) and Surgery Partners (SGRY)
TipRanks · 09/30 11:10
Immix Biopharma Is Maintained at Buy by Needham
Dow Jones · 09/29 17:04
Immix Biopharma Price Target Raised to $30.00/Share From $21.00 by Needham
Dow Jones · 09/29 17:04
More
Webull provides a variety of real-time IMMX stock news. You can receive the latest news about Immix Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.